Log in
Enquire now
‌

US Patent 10500229 Targeted disruption of the MHC cell receptor

Patent 10500229 was granted and assigned to Sangamo Therapeutics on December, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Sangamo Therapeutics
Sangamo Therapeutics
Current Assignee
Sangamo Therapeutics
Sangamo Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10500229
Date of Patent
December 10, 2019
Patent Application Number
15380723
Date Filed
December 15, 2016
Patent Citations Received
‌
US Patent 11661459 Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
0
‌
US Patent 11591381 Gene-edited natural killer cells
‌
US Patent 11459372 Gene-edited natural killer cells
Patent Primary Examiner
‌
Scott Long
Patent abstract

Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10500229 Targeted disruption of the MHC cell receptor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.